AE

ANNE ESPOSITO

AEGIS LLC · Washington, DC · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
2
last 3 years
Filings
4
3 agencies contacted
Activity
filings by quarter
Works on

Background

Government experience
Health Policy Coordinator
Energy and Commerce Committee; Health Policy Advisor, Health Subcommittee
Chairman Bilirakis
Disclosed on LD-2 filings
Career
Washington, DC
2024 - present

Specific issues

ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving).
Pharmacy · 2024 Q3
General health care issues.
Health Issues · 2024 Q3
PBM reforms. 340B. IRA implementation. Drug pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2973 - Modernizing and Ensuring PBM Accountability Act. H.R.830 - HELP Copays Act. H.R.7085 - BIOSECURE Act. S.127 - Pharmacy Benefit Manager Transparency Act of 2023. S.1339 - Pharmacy Benefit Manager Reform Act H.R.3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.
Pharmacy · 2024 Q3
PBM reforms. 340B. IRA implementation. Drug pricing. General health care issues.
Health Issues · 2024 Q3

Filing history

2024 Q3
TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS
Q3lda.gov →
2024 Q3
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Q3lda.gov →
2024 Q3
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
RRlda.gov →
2024 Q3
TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS
RRlda.gov →
Showing recent filings · full history on lda.gov